Sunday, August 23, 2020

BioMarin (BMRN) Stock Plunges After FDA Doesn't Approve Gene Therapy

BioMarin, the frontrunner in the hemophilia A gene therapy race, went to the FDA armed with several years of data from a phase 1/2 study and interim ...
http://dlvr.it/Rf9VmL
-

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...